Clinical impact of intratumoral HER2 heterogeneity on trastuzumab eficacy
| Project/Area Number |
15K10123
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Japanese Foundation for Cancer Research |
|---|
Principal Investigator |
Wakatsuki Takeru 公益財団法人がん研究会, 有明病院 消化器内科, 副医長 (60443876)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Yamamoto Noriko 公益財団法人がん研究会, がん研究所 病理部, 主任研究員 (10280629)
Mashima Tetsuo 公益財団法人がん研究会, がん化学療法センター 分子生物治療研究部, 主任研究員 (30311228)
Mori Seiichi 公益財団法人がん研究会, がんプレシジョン医療研究センター 次世代がん研究シーズ育成プロジェクト, プロジェクトリーダー (10334814)
Sano Takeshi 公益財団法人がん研究会, 有明病院, 副院長 (30215884)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | HER2 / Gastric cancer / HER2 heterogeneity / Trastuzumab / Biomarker / 胃癌 / HER2 heterigeneity / トラスツズマブ / 治療効果予測因子 / Heterogeneity / Gastric Cancer |
|---|
| Outline of Final Research Achievements |
Intratumoral HER2 heterogeneity is ofted seen in gastric cancer. We evaluated an association between HER2 heterogeneity and trasutuzumab efficacy. We obtained new findings as follows; 1: When used surgical specimens, patients whose tumor homogeneously overexpressed HER2 protein had substantial benefit from trastuzumab. 2: When used biopsy specimens, similar results were obtained but its impact was modest compared with surgical specimens. 3: patients whose tumor heterogeneously overexpressed HER2 protein had modest benefit regardless types of tumor sample. HER2 heterogeneity in surgical specimens is useful biomarker as a positive predictor for anti-HER2 agents, while HER2 heterogeneity in biopsy specimens should be used as a negative predictor.
|
Report
(4 results)
Research Products
(6 results)
